Enfusion (Enfusion) Debt-to-Equity : 0.29 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Enfusion Debt-to-Equity?

Enfusion's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4.3 Mil. Enfusion's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $11.2 Mil. Enfusion's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $53.7 Mil. Enfusion's debt to equity for the quarter that ended in Dec. 2023 was 0.29.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Enfusion's Debt-to-Equity or its related term are showing as below:

ENFN' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.42 Med: -0.06 Max: 0.29
Current: 0.29

During the past 5 years, the highest Debt-to-Equity Ratio of Enfusion was 0.29. The lowest was -0.42. And the median was -0.06.

ENFN's Debt-to-Equity is ranked worse than
57.46% of 2226 companies
in the Software industry
Industry Median: 0.21 vs ENFN: 0.29

Enfusion Debt-to-Equity Historical Data

The historical data trend for Enfusion's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enfusion Debt-to-Equity Chart

Enfusion Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.24

-0.42

0.11

0.29

Enfusion Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial											0.11	0.21	0.27	0.33	0.29

Competitive Comparison of Enfusion's Debt-to-Equity

For the Software - Application subindustry, Enfusion's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enfusion's Debt-to-Equity Distribution in the Software Industry

For the Software industry and Technology sector, Enfusion's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Enfusion's Debt-to-Equity falls into.

Enfusion Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Enfusion's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.256	+	11.181)	/	53.666
	=	0.29

Enfusion's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.256	+	11.181)	/	53.666
	=	0.29

Enfusion (NYSE:ENFN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Enfusion Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Enfusion's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Enfusion (Enfusion) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Technology » Software » Enfusion Inc (NYSE:ENFN) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

125 South Clark Street, Suite 750, Chicago, IL, USA, 60603

Website

https://www.enfusion.com

Enfusion Inc is a software-as-a-service (SaaS) provider focused on transforming the investment management industry. Its solutions are designed to eliminate technology and information barriers, empowering investment managers to make and execute better-informed investment decisions in real-time. It simplifies investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset resulting in a single source of truth.

Executives

Deirdre Somers	director	C/O ENFUSION, INC., 125 SOUTH CLARK STREET, SUITE 750, CHICAGO IL 60603
Bradley Herring	officer: Chief Financial Officer	C/O SHIFT4 PAYMENTS, INC., 2202 N. IRVING STREET, ALLENTOWN PA 16109
Oleg Movchan	director, 10 percent owner	C/O ENFUSION INC., 125 SOUTH CLARK ST. STE 750, CHICAGO IL 60603
Bronwen Bastone	officer: Chief People Officer	C/O ENFUSION, INC., 125 SOUTH CLARK STREET SUITE 750, CHICAGO IL 60603
Stephen Malherbe	10 percent owner	C/O ENFUSION, INC., 125 SOUTH CLARK STREET, SUITE 750, CHICAGO IL 60603
Dan Groman	officer: Chief Technology Officer	C/O ENFUSION INC., 125 SOUTH CLARK STREET STE. 750, CHICAGO IL 60603
Tarek Hammoud	10 percent owner	C/O ENFUSION INC., 125 SOUTH CLARK ST. STE. 750, CHICAGO IL 60603
Ftv Investment Holdings, L.p.	10 percent owner	601 CALIFORNIA STREET, FLOOR 19, SAN FRANCISCO CA 94108
Michael Spellacy	director	399 PARK AVENUE, NEW YORK NY 10022
Quiet Light Securities, Llc	10 percent owner	70 WEST MADISON, SUITE 1675, CHICAGO IL 60602
Steven M. Bachert	officer: Chief Revenue Officer	C/O ENFUSION INC., 125 SOUTH CLARK ST., STE 750, CHIGAGO IL 60603
Lra Ventures, Llc	10 percent owner	C/O ENFUSION, INC., 125 SOUTH CLARK STREET, SUITE 750, CHICAGO IL 60603
Hillhouse Investment Management, Ltd.	10 percent owner	OFFICE #122, WINDWARD 3 BUILDING, REGATTA OFFICE PARK, WEST BAY ROAD, GRAND CAYMAN E9 KY1-9006
Roy Luo	director	394 PACIFIC AVENUE, 2ND FLOOR, SAN FRANCISCO CA 94111
Iconiq Strategic Partners V-b, L.p.	10 percent owner	394 PACIFIC AVENUE, SECOND FLOOR, SAN FRANCISCO CA 94111